AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31427321 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK's split-virion inactivated quadrivalent influenza vaccine
Number of subjects: 1000
Study 31428442 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized electronic registry for monitoring men on active surveillance
Number of subjects: 0
Study 31428443 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, moderate-intensity exercise intervention consisting of aerobic and strengthening components for 12 weeks.
Number of subjects: 30
Study 31428443 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, moderate-intensity exercise intervention.
Number of subjects: 30
Study 31428515 — intervention group
Group type: EXPERIMENTAL
Intervention: Padi4 deficient mice
Number of subjects: 0
Study 31428515 — intervention group
Group type: COMPARATOR
Intervention: Control group (wild-type mice)
Number of subjects: 0
Study 31428530 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 33
Study 31428530 — intervention group
Group type: COMPARATOR
Intervention: Bosutinib
Number of subjects: 33
Study 31428637 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneophysiotherapeutic procedures (radon water therapy) for 21 days
Number of subjects: 34
Study 31428637 — intervention group
Group type: COMPARATOR
Intervention: Control group (17 employees of the spa suffering from osteoarthritis)
Number of subjects: 34
Study 31429027 — intervention group
Group type: EXPERIMENTAL
Intervention: Bavituximab 3 mg/kg weekly and Sorafenib 400 mg twice daily
Number of subjects: 38
Study 31429027 — intervention group
Group type: EXPERIMENTAL
Intervention: Bavituximab and Sorafenib combination
Number of subjects: 38
Study 31429417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic (PGx) testing results released to primary care physician immediately after results are available
Number of subjects: 52
Study 31429417 — intervention group
Group type: COMPARATOR
Intervention: Pharmacogenomic (PGx) testing results released to primary care physician after 3 months
Number of subjects: 52
Study 31429722 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline-containing regimens
Number of subjects: 2600
Study 31429722 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid-containing regimens
Number of subjects: 2600
Study 31429798 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week strength/endurance training program (18 sessions)
Number of subjects: 2
Study 31430294 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth lifestyle intervention (digital application)
Number of subjects: 50
Study 31430318 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect adherence measures (Medication Possession Ratio, Pill Count, Self-Report)
Number of subjects: 375
Study 31430405 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical digoxin and furosemide gel
Number of subjects: 0
Study 31430405 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31431116 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus in HFrEF
Number of subjects: 6167
Study 31431116 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus in HFpEF
Number of subjects: 6167
Study 31431116 — intervention group
Group type: COMPARATOR
Intervention: No diabetes mellitus
Number of subjects: 6167
Study 31431117 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital care for heart failure
Number of subjects: 10004
Study 31431117 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilization of diagnostic tests
Number of subjects: 10004
Study 31431117 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription rates of guideline-recommended medications
Number of subjects: 10004
Study 31431117 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up appointments
Number of subjects: 10004
Study 31431117 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilization of traditional Chinese medicine
Number of subjects: 10004
Study 31431387 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT of the primary tumor
Number of subjects: 10
Study 31431387 — intervention group
Group type: EXPERIMENTAL
Intervention: FRT to the lymph nodes
Number of subjects: 10
Study 31431387 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT and FRT combined
Number of subjects: 10
Study 31431673 — intervention group
Group type: EXPERIMENTAL
Intervention: GFRA1 methylation-positive patients
Number of subjects: 198
Study 31431673 — intervention group
Group type: EXPERIMENTAL
Intervention: ZNF382 methylation-positive patients
Number of subjects: 198
Study 31431673 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk GC patients (based on GFRA1 and ZNF382 methylation)
Number of subjects: 198
Study 31431673 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk GC patients
Number of subjects: 198
Study 31431932 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Protein Sparing Modified Fast (rPSMF)
Number of subjects: 0
Study 31431956 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness perceptions in SLE patients
Number of subjects: 241
Study 31431956 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness perceptions in SSc patients
Number of subjects: 241
Study 31431998 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ-SC 162 mg once weekly for 52 weeks (monotherapy)
Number of subjects: 161
Study 31431998 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ-SC 162 mg once weekly for 52 weeks (combination therapy with csDMARDs)
Number of subjects: 161
Study 31431998 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ-SC (both monotherapy and combination therapy)
Number of subjects: 161
Study 31432451 — intervention group
Group type: EXPERIMENTAL
Intervention: Under-dosing of rivaroxaban (less than 15 mg once daily)
Number of subjects: 6521
Study 31433059 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE (1000mg ceftriaxone/500mg sulbactam/37mg disodium EDTA) every 12h
Number of subjects: 230
Study 31433059 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (1000mg) every 8h
Number of subjects: 230
Study 31433472 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 4336
Study 31433489 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-Care Pharmacogenomic Decision Support
Number of subjects: 0
Study 31433489 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31433708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR)
Number of subjects: 46
Study 31433708 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy
Number of subjects: 46
Study 31433768 — intervention group
Group type: EXPERIMENTAL
Intervention: Defining clinical roles and responsibilities
Number of subjects: 791
Study 31433768 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 791
Study 31433768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hiring staff to perform discharge medication reconciliation
Number of subjects: 791
Study 31433768 — intervention group
Group type: EXPERIMENTAL
Intervention: Training staff to take medication histories
Number of subjects: 791
Study 31433768 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementing a new electronic health record (EHR)
Number of subjects: 791
Study 31433920 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral selinexor (80 mg) plus dexamethasone (20 mg) twice weekly
Number of subjects: 122
Study 31434508 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 97
Study 31434543 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity stepping (70%-80% heart rate reserve) of variable, difficult stepping tasks (high variable)
Number of subjects: 97
Study 31434543 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity stepping performing only forward walking (high forward)
Number of subjects: 97
Study 31434543 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity stepping in variable contexts at 30% to 40% heart rate reserve (low variable)
Number of subjects: 97
Study 31434543 — intervention group
Group type: EXPERIMENTAL
Intervention: High-variable training
Number of subjects: 97
Study 31434543 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training
Number of subjects: 97
Study 31434769 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-related knowledge and attitudes in Chiang Rai
Number of subjects: 2141
Study 31434769 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-related knowledge and attitudes in Salavan
Number of subjects: 2141
Study 31434769 — intervention group
Group type: EXPERIMENTAL
Intervention: Local expressions for antibiotics in Chiang Rai
Number of subjects: 2141
Study 31434783 — intervention group
Group type: EXPERIMENTAL
Intervention: Household survey regarding influenza-like illness (ILI) and vaccination during the 2015/2016 season
Number of subjects: 0
Study 31434783 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of influenza viruses collected during the 2016/2017 season using whole genome sequencing (WGS)
Number of subjects: 0
Study 31434783 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of influenza-specific antibody titres against all vaccinated and circulated strains during the 2016/2017 season
Number of subjects: 0
Study 31434783 — intervention group
Group type: EXPERIMENTAL
Intervention: Linking survey data and PCR-confirmed cases to Statistics Office data
Number of subjects: 0
Study 31434783 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylodynamic analyses of WGS data in the context of patient epidemiological data
Number of subjects: 0
Study 31434793 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg per day orally plus another aromatase inhibitor
Number of subjects: 18
Study 31434940 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy in TNBC (n=239)
Number of subjects: 3520
Study 31434940 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine treatment in ER+/HER2-/LN- (n=1113)
Number of subjects: 3520
Study 31434940 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine treatment in ER+/HER2-/LN+ (n=423)
Number of subjects: 3520
Study 31434940 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy and endocrine treatment in HER2+/ER+ (n=239)
Number of subjects: 3520
Study 31434940 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy and endocrine treatment in ER+/HER2-/LN+ (n=433)
Number of subjects: 3520
Study 31434940 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine treatment in ER+/HER2-/LN- untreated (n=200)
Number of subjects: 3520
Study 31434940 — intervention group
Group type: EXPERIMENTAL
Intervention: TNBC-untreated (n=82)
Number of subjects: 3520
Study 31434940 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2+/ER- with anti-HER2+ ACT treatment (n=110)
Number of subjects: 3520
Study 31434940 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2+/ER+ with anti-HER2+ ACT + endocrine treatment (n=239)
Number of subjects: 3520
Study 31435905 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprocitentan
Number of subjects: 16
Study 31436599 — intervention group
Group type: EXPERIMENTAL
Intervention: Informing participants about their diagnosis of HAND
Number of subjects: 139
Study 31437454 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided liver biopsy (EUS-LB) sampling using a 22-gauge fork-tip core biopsy needle
Number of subjects: 41
Study 31437454 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided liver biopsy (EUS-LB) sampling
Number of subjects: 41
Study 31438761 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone telemedicine intervention
Number of subjects: 7
Study 31438885 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell (BMMC) transplantation
Number of subjects: 25
Study 31438926 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation Prediction Score (DiPS) using logistic regression and support vector machine methods
Number of subjects: 210
Study 31438926 — intervention group
Group type: EXPERIMENTAL
Intervention: DiPS scores for resource allocation in physical activity intervention programs
Number of subjects: 210
Study 31439037 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI0680 administered intravenously at doses of 0.1, 0.5, 2.5, 10, or 20 mg/kg Q2W or Q3W, with some cohorts receiving 20 mg/kg once a week for 2 or 4 weeks, then 20 mg/kg Q2W for a total treatment duration of 12 months or until progression.
Number of subjects: 58
Study 31439037 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI0680
Number of subjects: 58
Study 31439295 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI Ready ICD system
Number of subjects: 220
Study 31439296 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ventricular arrhythmias (VAs) occurring <30 days post-LVAD implantation
Number of subjects: 652
Study 31439296 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients discharged alive from hospital
Number of subjects: 652
Study 31439537 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib at a dose of 20 mg/m²
Number of subjects: 9
Study 31439586 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical tumor resection
Number of subjects: 36
Study 31439586 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of ctDNA on the third day after R0 resection
Number of subjects: 36
Study 31439586 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residual disease (MRD) detection
Number of subjects: 36
Study 31439614 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 26
Study 31439614 — intervention group
Group type: EXPERIMENTAL
Intervention: CPM score
Number of subjects: 26
Study 31439873 — intervention group
Group type: EXPERIMENTAL
Intervention: high-frequency tRNS (100-640 Hz; 2 mA; 20 minutes)
Number of subjects: 30
Study 31439873 — intervention group
Group type: EXPERIMENTAL
Intervention: high-frequency tRNS
Number of subjects: 30
Study 31439873 — intervention group
Group type: COMPARATOR
Intervention: rTMS
Number of subjects: 30
Study 31440186 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-to-moderate exercise program (4 times a week for 5 weeks)
Number of subjects: 23
Study 31440186 — intervention group
Group type: COMPARATOR
Intervention: Intensive exercise program (4 times a week for 5 weeks)
Number of subjects: 23
Study 31440489 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental Coach System
Number of subjects: 0
Study 31440489 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31440722 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (adjunctive therapy)
Number of subjects: 311
Study 31440722 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (adjunctive therapy) in SCB (+) subgroup (n=149)
Number of subjects: 311
Study 31440722 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (adjunctive therapy) in SCB (-) subgroup (n=153)
Number of subjects: 311
Study 31440853 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation with 0.9% saline
Number of subjects: 434
Study 31440853 — intervention group
Group type: COMPARATOR
Intervention: Resuscitation with 3% saline
Number of subjects: 434
Study 31440945 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental craniopharyngiomas (incCP)
Number of subjects: 218
Study 31440945 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic craniopharyngiomas (symCP)
Number of subjects: 218
Study 31440945 — intervention group
Group type: COMPARATOR
Intervention: Comparison of incCP and symCP
Number of subjects: 218
Study 31440946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide (subcutaneous)
Number of subjects: 127
Study 31441351 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 3501
Study 31441351 — intervention group
Group type: COMPARATOR
Intervention: No diabetes mellitus
Number of subjects: 3501
Study 31441881 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL in patients with good neurologic outcomes
Number of subjects: 75
Study 31441881 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL in survived group
Number of subjects: 75
Study 31441881 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL predictive performance for neurologic outcome
Number of subjects: 75
Study 31441881 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL correlation with 28-day mortality
Number of subjects: 75
Study 31442103 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 at 3.6 mg/kg intravenously every 3 weeks plus neratinib at 120, 160, 200, or 240 mg/d orally
Number of subjects: 27
Study 31442103 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 at 3.6 mg/kg intravenously every 3 weeks plus neratinib at 160 mg/d orally
Number of subjects: 27
Study 31442103 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 at 3.6 mg/kg intravenously every 3 weeks plus neratinib (various doses)
Number of subjects: 27
Study 31442277 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 74
Study 31442327 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 re-treatment (up to 6 additional injections)
Number of subjects: 44
Study 31442616 — intervention group
Group type: EXPERIMENTAL
Intervention: Discogenic cells injected intradiscally in a rabbit model of DD
Number of subjects: 0
Study 31442616 — intervention group
Group type: EXPERIMENTAL
Intervention: Discogenic cells injected subcutaneously in nude mice
Number of subjects: 0
Study 31442616 — intervention group
Group type: COMPARATOR
Intervention: Control discs or injection of vehicle alone (no cells)
Number of subjects: 0
Study 31442817 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks) + Metronomic cyclophosphamide (50 mg b.i.d. one week on and one week off)
Number of subjects: 17
Study 31442817 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study 31443253 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 transmitted/founder (T/F) viruses in the CNS
Number of subjects: 0
Study 31443253 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-genome sequencing of envelope gene
Number of subjects: 0
Study 31443343 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical supervision with dietary recommendations
Number of subjects: 0
Study 31443741 — intervention group
Group type: EXPERIMENTAL
Intervention: Samalizumab (50 to 600 mg/m)
Number of subjects: 26
Study 31443741 — intervention group
Group type: EXPERIMENTAL
Intervention: Samalizumab
Number of subjects: 26
Study 31443976 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated type II endoleak
Number of subjects: 197
Study 31443976 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II endoleak
Number of subjects: 197
Study 31443976 — intervention group
Group type: COMPARATOR
Intervention: Early type II endoleak
Number of subjects: 197
Study 31444088 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Geriatric Assessment (mGA) including Geriatric Depression Scale-15 (GDS) and Timed Up and Go (TUG)
Number of subjects: 307
Study 31444088 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth mixture model for PF trajectories
Number of subjects: 307
Study 31444088 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment pain and dyspnea
Number of subjects: 307
Study 31444088 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms, reduced mobility, and more physical symptoms
Number of subjects: 307
Study 31444186 — intervention group
Group type: EXPERIMENTAL
Intervention: Care in a neonatal intensive care unit (NICU)
Number of subjects: 0
Study 31444186 — intervention group
Group type: COMPARATOR
Intervention: Care in a local neonatal unit (LNU)
Number of subjects: 0
Study 31444190 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative monitoring of haemodynamic measurements such as the Toe-Brachial Index during endovascular surgery.
Number of subjects: 80
Study 31444250 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD19 JWCAR029 CAR T cells
Number of subjects: 10
Study 31444600 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate
Number of subjects: 586
Study 31444849 — intervention group
Group type: EXPERIMENTAL
Intervention: SSM@100Hz
Number of subjects: 260
Study 31444849 — intervention group
Group type: EXPERIMENTAL
Intervention: Baveno VI criteria + SSM@100Hz
Number of subjects: 260
Study 31444849 — intervention group
Group type: COMPARATOR
Intervention: Baveno VI criteria + SSM@50Hz
Number of subjects: 260
Study 31444849 — intervention group
Group type: COMPARATOR
Intervention: Baveno VI criteria alone
Number of subjects: 260
Study 31445199 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks for up to 2 years
Number of subjects: 1008
Study 31445199 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 1008
Study 31446142 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered electronic screening for SUD risk, depression and anxiety using TAPS and AOQ measures
Number of subjects: 5000
Study 31446142 — intervention group
Group type: COMPARATOR
Intervention: Usual care (24-month period prior to intervention)
Number of subjects: 5000
Study 31446511 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide 240 mg once-daily for 1 week, followed by continuous daily dosing (4 weeks/cycle)
Number of subjects: 6
Study 31446987 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (Rova-T) 0.2 or 0.3 mg/kg by intravenous infusion on Day 1 of each 6-week cycle for 2 doses and dexamethasone (8 mg BID oral) on D-1, D1, and D2 of each 6-week cycle
Number of subjects: 29
Study 31447247 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition care quality indicators (QIs)
Number of subjects: 46
Study 31447780 — intervention group
Group type: EXPERIMENTAL
Intervention: A1C test
Number of subjects: 0
Study 31448107 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program after total hip arthroplasty, details not available
Number of subjects: 0
Study 31448107 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details not available
Number of subjects: 0
Study 31448107 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program after total hip arthroplasty, details on dosage and duration not available.
Number of subjects: 0
Study 31448107 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0